The characteristic changes of GLP-1 face include 4,5 : Facial volume loss, particularly in the midface Periocular hollowing and periorbital volume depletion Dermal thinning with loss of collagen and elastin fibers Decreased skin elasticity leading to redundant skin folds Accelerated appearance of aging As a result of these facial changes, GLP-1 agonist medications can result in an older, haggard and tired looking appearance
Manufacturers are therefore maintaining dual formulation strategies to capture both segments while extending product life cycles through delivery innovation
Retatrutide is an investigational triple-agonist that is not currently FDA-approved for clinical weight-loss use
In addition to structural damage, sexual morbidity remains a major but often underappreciated consequence of brachytherapy [107, 113]
1,6 These mechanisms are part of why the muscle effect shows up only when training is in the picture: the energy advantage gets you a little more work done, and the cellular and satellite cell responses amplify the adaptations to that work